ATNM Latest Press Releases

-- October 23, 2026 --

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 PRNewswire 8:00 AM

-- October 20, 2026 --

Actinium Pharmaceuticals Unveils ATNM-400 Data at EANM 2026 with a First-In-Human HER3-Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer PRNewswire 8:01 AM

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models PRNewswire 7:30 AM

-- October 19, 2026 --

Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 PRNewswire 7:31 AM

-- October 16, 2026 --

Actinium Pharmaceuticals Announces Inducement Grants to New Employees PRNewswire 5:00 PM

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models PRNewswire 8:31 AM

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development PRNewswire 7:30 AM

-- October 15, 2026 --

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer PRNewswire 8:31 AM

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer PRNewswire 7:30 AM

-- September 4, 2026 --

Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference PRNewswire 5:05 PM

-- August 14, 2026 --

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update PRNewswire 5:03 PM

-- June 3, 2026 --

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer PRNewswire 8:00 AM

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models PRNewswire 7:25 AM

-- June 1, 2026 --

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development PRNewswire 8:00 AM

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates PRNewswire 7:00 AM

Market Data Delayed 15 Minutes